Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 8:52 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–35 of 35 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: ALK Genes Clear all
Withdrawn Phase 2 Interventional

Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers

NCT03868423
View directory record Official record
Conditions
Advanced Malignant Neoplasm, ALK Fusion Protein Expression, ALK Gene Amplification, ALK Gene Mutation, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Neoplasm in the Central Nervous System, Metastatic Malignant Solid Neoplasm, ROS1 Fusion Positive, ROS1 Gene Amplification, ROS1 Gene Mutation
Interventions
Brigatinib, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
Sameek Roychowdhury
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 18, 2022 · Synced Nov 11, 2026, 8:52 AM EST
Completed No phase listed Observational

Molecular Determinants of Acquired Clinical Resistance to Crizotinib in Non-small Cell Lung Cancer Harboring a Translocation or Inversion Event Involving the ALK Gene Locus

NCT01300429
View directory record Official record
Conditions
Lung Cancer
Interventions
obtain tissue specimens
Genetic
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 7, 2021 · Synced Nov 11, 2026, 8:52 AM EST
Completed Phase 3 Interventional Results available

An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

NCT00932893
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
PF-02341066, Pemetrexed, Docetaxel
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
119
States / cities
Little Rock, Arkansas • Bakersfield, California • Beverly Hills, California + 58 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2017 · Synced Nov 11, 2026, 8:52 AM EST
Active, not recruiting Phase 2 Interventional

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

NCT02568267
View directory record Official record
Conditions
Breast Cancer, Cholangiocarcinoma, Colorectal Cancer, Head and Neck Neoplasms, Lymphoma, Large-Cell, Anaplastic, Melanoma, Neuroendocrine Tumors, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Papillary Thyroid Cancer, Primary Brain Tumors, Renal Cell Carcinoma, Sarcomas, Salivary Gland Cancers, Adult Solid Tumor
Interventions
Entrectinib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
534 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
48
States / cities
Phoenix, Arizona • Duarte, California • La Jolla, California + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Nov 11, 2026, 8:52 AM EST
Active, not recruiting Phase 1Phase 2 Interventional

Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options

NCT02650401
View directory record Official record
Conditions
Solid Tumors, CNS Tumors
Interventions
Entrectinib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
0 Years to 18 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
15
States / cities
La Jolla, California • San Francisco, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Nov 11, 2026, 8:52 AM EST
Completed Phase 2 Interventional Results available

Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475

NCT03049618
View directory record Official record
Conditions
ALK Gene Mutation, BRAF Gene Mutation, EGFR Gene Mutation, Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Carcinoma, Recurrent Head and Neck Carcinoma, Recurrent Non-Small Cell Lung Carcinoma, ROS1 Gene Mutation, Stage III Non-Small Cell Lung Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
Interventions
Laboratory Biomarker Analysis, Pembrolizumab, Recombinant EphB4-HSA Fusion Protein
Other · Biological
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Nov 11, 2026, 8:52 AM EST
Completed Phase 2 Interventional

A Study of Ganetespib in Subjects With ALK-Positive Non-Small-Cell Lung Cancer (NSCLC)

NCT01562015
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Ganetespib
Drug
Lead sponsor
Synta Pharmaceuticals Corp.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Tampa, Florida • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 20, 2015 · Synced Nov 11, 2026, 8:52 AM EST
Recruiting Phase 1 Interventional

Study of SGR-1505 in Mature B-Cell Neoplasms

NCT05544019
View directory record Official record
Conditions
Mature B-Cell Neoplasm, Non Hodgkin Lymphoma, DLBCL, Waldenstrom Macroglobulinemia, MALT Lymphoma, Follicular Lymphoma, Pediatric-Type Follicular Lymphoma, IRF4 Gene Rearrangement, EBV-Positive DLBCL, Nos, Burkitt Lymphoma, Plasmablastic Lymphoma, High-grade B-cell Lymphoma, Primary Cutaneous Follicle Center Lymphoma, Primary Effusion Lymphoma, Mantle Cell Lymphoma, DLBCL Germinal Center B-Cell Type, Primary Mediastinal Large B Cell Lymphoma, T-Cell/Histiocyte Rich Lymphoma, ALK-Positive Large B-Cell Lymphoma, Primary Cutaneous Diffuse Large B-Cell Lymphoma, Splenic Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, Nodal Marginal Zone Lymphoma, HHV8-Positive DLBCL, Nos, Lymphoplasmacytic Lymphoma, Duodenal-Type Follicular Lymphoma
Interventions
SGR-1505
Drug
Lead sponsor
Schrödinger, Inc.
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
16
States / cities
Gilbert, Arizona • Newark, Delaware • Pompano Beach, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Nov 11, 2026, 8:52 AM EST
Recruiting No phase listed Observational

Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy

NCT03042221
View directory record Official record
Conditions
Non-Small Cell Carcinoma of Lung, TNM Stage 4, Non-Small Cell Lung Cancer, EGFR Gene Mutation, ALK Gene Mutation, ROSE Cluster 1, BRAF V600E
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Nov 11, 2026, 8:52 AM EST
Terminated Phase 2 Interventional Results available

A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors

NCT04644315
View directory record Official record
Conditions
Neoplasms, Colorectal Neoplasms, Melanoma, Pancreatic Neoplasms, Sarcoma, Ovarian Neoplasms, Brain Neoplasms, Thyroid Neoplasms, Neuroendocrine Tumors, Cholangiocarcinoma, Salivary Gland Neoplasms, Head and Neck Neoplasms, Thyroid Cancer, Papillary, Lymphoma, Large-Cell, Anaplastic, Neoplasms by Site, Respiratory Tract Neoplasms, Thoracic Neoplasms, Respiratory Tract Diseases, Carcinoma, Bronchogenic, Bronchial Neoplasms, Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms, Digestive System Diseases, Gastrointestinal Diseases, Colonic Diseases, Intestinal Diseases, Central Nervous System
Interventions
Alectinib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
29
States / cities
Culver City, California • Los Angeles, California • Sacramento, California + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2023 · Synced Nov 11, 2026, 8:52 AM EST